MXPA03005515A - Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1. - Google Patents

Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.

Info

Publication number
MXPA03005515A
MXPA03005515A MXPA03005515A MXPA03005515A MXPA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A MX PA03005515 A MXPA03005515 A MX PA03005515A
Authority
MX
Mexico
Prior art keywords
mglur
azepine
thieno
pyrazine
benzo
Prior art date
Application number
MXPA03005515A
Other languages
English (en)
Spanish (es)
Inventor
Binggeli Alfred
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MXPA03005515A publication Critical patent/MXPA03005515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA03005515A 2000-12-22 2001-12-11 Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1. MXPA03005515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00128329 2000-12-22
PCT/EP2001/014527 WO2002051418A1 (en) 2000-12-22 2001-12-11 Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists

Publications (1)

Publication Number Publication Date
MXPA03005515A true MXPA03005515A (es) 2003-09-25

Family

ID=8170787

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005515A MXPA03005515A (es) 2000-12-22 2001-12-11 Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.

Country Status (17)

Country Link
US (1) US6586422B2 (enExample)
EP (1) EP1345609B1 (enExample)
JP (1) JP4077319B2 (enExample)
KR (1) KR100545906B1 (enExample)
CN (1) CN1260226C (enExample)
AR (1) AR032379A1 (enExample)
AT (1) ATE297734T1 (enExample)
AU (1) AU2002216095B2 (enExample)
BR (1) BR0116378A (enExample)
CA (1) CA2432077C (enExample)
DE (1) DE60111568T2 (enExample)
DK (1) DK1345609T3 (enExample)
ES (1) ES2243400T3 (enExample)
MX (1) MXPA03005515A (enExample)
PT (1) PT1345609E (enExample)
WO (1) WO2002051418A1 (enExample)
ZA (1) ZA200304557B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
MX2008009178A (es) * 2006-01-19 2008-12-05 Athersys Inc Tiofenil y pirrolil acepinas como ligandos del receptor de serotonina 5-ht2c y sus usos.
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
CA2662491A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
KR101100864B1 (ko) * 2009-06-12 2012-01-02 양준호 자동차 광택기용 광택패드

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3136654A1 (de) 1981-09-16 1983-03-31 Zahnradfabrik Friedrichshafen Ag, 7990 Friedrichshafen Linearverschieblicher arbeitsarm, insbesondere fuer handhabungsgeraete
EP1059090A4 (en) * 1998-03-03 2002-02-27 Yamanouchi Pharma Co Ltd DRUGS AGAINST BLEEDING OF THE BRAIN
PT1117403E (pt) * 1998-10-02 2004-04-30 Sibia Neurosciences Inc Antagonistas de mglurs para o tratamento da dor e ansiedade
GB9823847D0 (en) * 1998-11-02 1998-12-23 Lilly Co Eli Pharmaceutical compounds
EP1074549B1 (en) * 1999-08-06 2003-11-19 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors
ES2209728T3 (es) * 1999-08-06 2004-07-01 F. Hoffmann-La Roche Ag Tetrahidro-benzo(d)azepinas y su uso como antagonistas de receptores de glutamato metabotropico.

Also Published As

Publication number Publication date
CN1487831A (zh) 2004-04-07
ATE297734T1 (de) 2005-07-15
DE60111568D1 (de) 2005-07-21
AU2002216095B2 (en) 2005-12-01
KR100545906B1 (ko) 2006-01-26
PT1345609E (pt) 2005-08-31
CN1260226C (zh) 2006-06-21
EP1345609B1 (en) 2005-06-15
WO2002051418A1 (en) 2002-07-04
ES2243400T3 (es) 2005-12-01
CA2432077A1 (en) 2002-07-04
DK1345609T3 (da) 2005-10-03
CA2432077C (en) 2011-01-18
EP1345609A1 (en) 2003-09-24
BR0116378A (pt) 2003-10-28
KR20030062444A (ko) 2003-07-25
JP2004517850A (ja) 2004-06-17
DE60111568T2 (de) 2006-05-11
JP4077319B2 (ja) 2008-04-16
AR032379A1 (es) 2003-11-05
US6586422B2 (en) 2003-07-01
ZA200304557B (en) 2004-09-13
US20020123488A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
PT1073647E (pt) Derivados de 12,13-ciclopropano-epotilona
ZA200204380B (en) Partial or full A1 agonists-N6 heterocyclic 5'-thio substituted adenosine derivatives.
MXPA02007232A (es) Derivados aminados de dihidro-1,3,5-triazina y sus ojos terapeuticos.
IL162377A0 (en) 5,6-Diaryl-pyrazine-2-amide derivatives as cb1 antagonists
FR2806720B1 (fr) Derives de 2,2,6,6-diethyl-dimethyl-1-alcoxypiperidines et 1-oxydes correspondants
MXPA03005515A (es) Derivados de tetrahidro-(benzo o tieno)-azepina-pirazina y triazina como antagonistas de mglur 1.
IL155103A0 (en) Substituted c-cyclohexylmethylamine derivatives
EP1274431A4 (en) 10,11-DIFLUOROMETHYLENE DIOXYCAMTOTHECINE COMPOUNDS WITH TOPOISOMERASE-I INHIBITION
AU2489002A (en) Benzofuran and benzothiophene derivatives
ZA200203275B (en) H-annellated benzo[f]chromenes.
MXPA03002737A (es) Derivados sustituidos de 1-aminobutan-3-ol.
EP1270629A4 (en) polyacetal
MXPA02005070A (es) 1-benzazepinas sustituidas y derivados de las mismas.
PT1129079E (pt) Derivados de triazina 2,4-dissubstituidos
ZA200102392B (en) 1,2-Substituted 2,3-dihydro-1H-5,9-dioxacyclohepta [f] inden-7-ones and 7-substituted benzo [b] [1,4] dioxepin-3-ones.
GB2348942B (en) Bomblet
AU2163202A (en) 5-amino-1-pentene-3-ol substituted derivatives
ZA99171B (en) Piperazino derivatives as neurokinin antagonists.
GB0103850D0 (en) The pit
IL146305A0 (en) Imidazo-containing heterocyclic compounds, their compositions and uses
ZA200202868B (en) Use of thienopyrimidines.
HRP20020971A2 (en) 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-inhibitors
PL335215A1 (en) Method of obtaining polyetheroles with the 1,3,5-triazine ring
AU4137000A (en) Benzo((b)) thiophene sulfonamide-1, 1-dioxide derivatives and their use as antineoplastic agents
GB0001972D0 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
FG Grant or registration